Genomelink vs GE HealthCare
Side-by-side comparison of AI visibility scores, market position, and capabilities
DNA app store enabling users to upload Ancestry/23andMe raw data for additional trait and health insights; $3.3M revenue positioned to capture 23andMe users after its 2024 bankruptcy filing.
About
Genomelink is a San Francisco-based DNA app store and personalized genomics platform that allows users to upload raw DNA data from Ancestry, 23andMe, or other consumer DNA tests and access a marketplace of analysis apps covering ancestry, traits, health predispositions, and wellness insights. Founded in 2017 and backed by $4.5-9 million from 500 Global, Asymmetry Ventures, and 27 total investors, Genomelink generated $3.3 million in revenue in 2024 with a 22-person team, serving consumers who want more from their raw genetic data than the original testing company provides.
Chicago medical imaging and AI diagnostics (NASDAQ: GEHC) ~$19.7B FY2024 revenue; GE spinoff Jan 2023, Edison AI 100+ models, 4M+ installed devices, Alzheimer's PET tracer competing with Siemens Healthineers.
About
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designing, manufacturing, and servicing medical imaging systems, patient monitoring equipment, pharmaceutical diagnostics, and AI-powered clinical decision support software through approximately 51,000 employees in 160 countries. GE HealthCare was spun off from General Electric Company in January 2023 — one of the most significant healthcare demergers in history — and has operated as an independent public company building its own capital structure, R&D investment priorities, and operational identity separate from GE's industrial conglomerate structure. In fiscal year 2024, GE HealthCare reported revenues of approximately $19.7 billion, with its four business segments contributing: Imaging (MRI, CT, X-ray, molecular imaging — ~$9.1B), Ultrasound (~$3.0B), Patient Care Solutions (monitoring, anesthesia — ~$3.6B), and Pharmaceutical Diagnostics (PET/SPECT contrast agents — ~$2.6B). CEO Peter Arduini has prioritized accelerating GE HealthCare's AI integration across its imaging portfolio — the Edison AI platform (100+ AI models cleared or in development for radiology workflows) embeds AI-assisted detection, workflow optimization, and image quality enhancement into GE HealthCare scanners, positioning the company as a digital health platform rather than a hardware manufacturer.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.